Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
暂无分享,去创建一个
[1] M. Brown,et al. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. , 1980, Journal of lipid research.
[2] D. Blankenhorn,et al. The inheritance of familial hypercholesterolemia. , 1972, The American journal of medicine.
[3] H. Mabuchi,et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. , 1983, The New England journal of medicine.
[4] S. Moorjani,et al. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. , 1979, Atherosclerosis.
[5] Winkelmann Rk,et al. Cutaneous side effects from use of triparanol (MER-29): preliminary data on ichthyosis and loss of hair. , 1961 .
[6] D. Blankenhorn,et al. Coronary Disease in Familial Hypercholesterolemia , 1967, Circulation.
[7] M. Brown,et al. Regulation of plasma cholesterol by lipoprotein receptors. , 1981, Science.
[8] Y. Chao,et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. , 1982, The Journal of clinical investigation.
[9] M. Wiley,et al. Isopentenyladenine as a mediator of mevalonate-regulated DNA replication. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Adamany,et al. The role of phosphorylated dolichols in membrane glycoprotein biosynthesis: relation to cholesterol biosynthesis. , 1981, International review of cytology.
[11] B. Trumpower. New concepts on the role of ubiquinone in the mitochondrial respiratory chain , 1981, Journal of bioenergetics and biomembranes.
[12] H. G. Morgan,et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. , 1980, The New England journal of medicine.
[13] J. Kostis,et al. Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment. , 1981, Chest.
[14] B. Lewis,et al. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia. , 1982, Atherosclerosis.
[15] W. Castelli,et al. Summary Estimates of Cholesterol Used to Predict Coronary Heart Disease , 1983, Circulation.
[16] M J Malloy,et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. , 1981, The New England journal of medicine.
[17] G. Hitzenberger,et al. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. , 1982, Atherosclerosis.
[18] M. Brown,et al. Familial hypercholesterolemia: genetic, biochemical and pathophysiologic considerations. , 1975, Advances in internal medicine.
[19] D. Bilheimer,et al. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Thompson,et al. Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. , 1960, The Journal of biological chemistry.
[21] T. A. Miettinen,et al. Cholestyramine and ileal by‐pass in the treatment of familial hypercholesterolaemia , 1977, European journal of clinical investigation.
[22] R. Lees,et al. Adrenal cortical function in homozygous familial hypercholesterolemia. , 1983, Metabolism: clinical and experimental.
[23] J. Verter,et al. Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia , 1974, Circulation.
[24] Y. Chao,et al. Catabolism of low density lipoproteins by perfused rabbit livers: cholestyramine promotes receptor-dependent hepatic catabolism of low density lipoproteins. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[25] G. Thompson,et al. SUPERIORITY OF PARTIAL ILEAL BYPASS OVER CHOLESTYRAMINE IN REDUCING CHOLESTEROL IN FAMILIAL HYPERCHOLESTEROLAEMIA , 1981, The Lancet.
[26] R. Mahley,et al. Lipoprotein receptors and cholesterol homeostasis. , 1983, Biochimica et biophysica acta.
[27] R. Havel,et al. Therapy of hyperlipidemic states. , 1982, Annual review of medicine.
[28] R Monaghan,et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[29] D. Illingworth,et al. COLESTIPOL PLUS NICOTINIC ACID IN TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA , 1981, The Lancet.
[30] C. Glueck,et al. Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia. , 1972 .
[31] J. Strauss,et al. The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. , 1982, Endocrine reviews.
[32] R. Lees,et al. Results of colestipol therapy in Type II hyperlipoproteinemia. , 1976, Atherosclerosis.
[33] R. Laughlin,et al. Cataracts in patients treated with triparanol. , 1962, JAMA.